DTPx Therapeutics (UHN)

www.uhnresearch.ca
Innovation Type:
Therapeutics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Falcons' Fortunes, Prospects
DTPx Therapeutics (University Health Network) is aiming to prevent relapse in colorectal cancer patients using a novel cell-based immunotherapy targeting a newly identified group of hibernating and drug tolerant cancer cells.

Related news

Women-led health and biotech companies dominate FACIT's latest investments

On the globally-recognized Women’s Entrepreneurship Day, FACIT is pleased to announce investments in four breakthrough oncology innovations – all driven by women leaders. November 19th each year is a day to celebrate and showcase women’s contributions to advance communities and to strengthen their empowerment in the entrepreneurial ecosystem to drive economic impact. FACIT’s support of the four ventures, Virano Therapeutics, Hyivy Health, Tenomix Inc., and DTPx Therapeutics are representative of an asset portfolio where over one third are women-led or founded innovations, attracting one third of every dollar invested by FACIT – as much as ten times the average for the venture capital industry. Read More

New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition

The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.